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Abstract
Background: In 2014 the Swedish government assigned to The Public Health Agency of Sweden to conduct
studies to evaluate optimal use of existing antibiotic agents. The aim is to optimize drug use and dosing regimens
to improve the clinical efficacy. The present study was selected following a structured prioritizing process by
independent experts.
Methods: This phase IV study is a randomized, open-label, multicenter study with non-inferiority design regarding
the therapeutic use of penicillin V with two parallel groups. The overall aim is to study if the total exposure with
penicillin V can be reduced from 1000 mg three times daily for 10 days to 800 mg four times daily for 5 days when
treating Streptococcus pyogenes (Lancefield group A) pharyngotonsillitis. Patients will be recruited from 17 primary
health care centers in Sweden. Adult men and women, youth and children ≥6 years of age who consult for sore
throat and is judged to have a pharyngotonsillitis, with 3–4 Centor criteria and a positive rapid test for group A
streptococci, will be included in the study. The primary outcome is clinical cure 5–7 days after discontinuation of
antibiotic treatment. Follow-up controls will be done by telephone after 1 and 3 months. Throat symptoms,
potential relapses and complications will be monitored, as well as adverse events. Patients (n = 432) will be
included during 2 years.
Discussion: In the era of increasing antimicrobial resistance and the shortage of new antimicrobial agents it is
necessary to revisit optimal usage of old antibiotics. Old antimicrobial drugs are often associated with inadequate
knowledge on pharmacokinetics and pharmacodynamics and lack of optimized dosing regimens based on
randomized controlled clinical trials. If a shorter and more potent treatment regimen is shown to be equivalent
with the normal 10 day regimen this can imply great advantages for both patients (adherence, adverse events,
resistance) and the community (resistance, drug costs).
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Background
In 2014 the Swedish government assigned to The Public
Health Agency of Sweden to conduct studies to evaluate
existing antibiotic agents from new perspectives. The
aim is to optimise drug use and dosage regimens to im-
prove the clinical efficacy of existing antibiotics, and to
reduce ecological disturbances in the normal microbiota.
The clinical trial described below is one of the projects
prioritized by independent experts within this
assignment.
Pharyngotonsillitis is one of the most common infections
in primary health care (PHC) in Sweden [1] and accounts
for about 20 % of all antibiotic prescriptions within PHC
[2]. The estimated number of patients in Sweden treated
for pharyngotonsillitis is about 400,000 each year [3].
Streptococcus group A (GAS) is the most common bacter-
ial etiology and also the dominating reason for antibiotic
treatment [3]. According to the Swedish guidelines the rec-
ommendation is to treat pharyngotonsillitis with phenoxy-
methylpenicillin (penicillin V) if 3–4 Centor criteria [2] and
GAS is present [3]. The recommended dose for adults is
1000 mg penicillin V three times daily for 10 days which
corresponds to about 12 t of penicillin V each year in
Sweden, calculated on the basis of adult doses. The infec-
tion is most frequent among school children and young
adults, resulting in a somewhat lower total amount of con-
sumption [4].
According to present European and American guide-
lines, 10 days penicillin treatment is generally recom-
mended as first line treatment of streptococcal
pharyngotonsillitis [5, 6]. The historical reason for
10 days treatment duration with penicillin is mainly to
avoid serious complications like acute rheumatic fever
and glomerulonephritis. These conditions are currently
extremely rare in western countries [7]. According to a
Cochrane report from 2012 patients recover without
antibiotic therapy but treatment is sometimes advised to
hasten clinical resolution and prevent suppurative seque-
lae, like peritonsillitis, acute otitis media or sinusitis. Clin-
ical studies on shorter treatment duration with penicillin
for streptococcal pharyngotonsillitis are encouraged [8].
There are few published studies comparing 10 days
treatment duration with shorter treatment durations
with penicillin V. Three studies which were published in
the 1980s have been identified. Five versus 10 days
(250 mg three times daily and 800 mg twice daily
respectively) [9, 10] and 7 versus 10 days (500 mg three
times daily) [11] were studied. All of the studies con-
cluded that 10 days of treatment was preferable but in
the light of current knowledge of pharmacokinetics and
pharmacodynamics (PK/PD) the doses used in these
studies were suboptimal. The effect of beta-lactam anti-
biotics is dependent on time above the minimum inhibi-
tory concentration (MIC) of the unbound drug
concentration in serum (free drug time above MIC; fT >
MIC). Usually, the target is that 95–99 % of the popula-
tion should achieve a fT >MIC of around 30–40 % for
non-severe infections [12], also expressed as the popula-
tion target attainment for a given target. For beta-
lactams a more frequent dosing is preferred and the dos-
ing interval is more critical than the size of the dose
[12]. The dosing regimen 800 mg four times daily pro-
vides better target attainment compared to 1000 mg
three times daily (33 % fT >MIC compared to 25 %
fT >MIC at the breakpoint MIC 0.25 mg/L). Our hy-
pothesis is that the experimental dosage regimen
800 mg four times daily gives at least the same effi-
cacy, possibly better patient adherence and a signifi-
cantly lower total exposure.
In the present study we will examine if penicillin V
given four times daily for 5 days is non-inferior to the
currently recommended dose regimen of 10 days to pa-
tients with pharyngotonsillitis caused by streptococcus
group A. Reducing the treatment duration to 5 days will
almost halve the consumption of penicillin V for this in-
dication. A shorter treatment duration may potentially
improve patient adherence [13], cause less effect on the
human microbiota [14] as well as lower medicinal costs
for patients and community.
Methods
Aim
The overall aim is to study if the total exposure with an-
tibiotics can be reduced from 1000 mg three times daily
for 10 days to 800 mg four times daily for 5 days when
treating streptococcus group A pharyngotonsillitis with
penicillin V.
Design
This Phase IV study is a randomized, open-label, multi-
center study with non-inferiority design regarding the
therapeutic use of penicillin V with two parallel groups.
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Setting
Patients will be recruited from 17 primary health care
centers (PHCC) in the counties of Skåne, Kronoberg and
Västra Götaland in the southern of Sweden. The PHCCs
are representing both urban and rural regions.
Characteristics of the patients
Inclusion criteria
Adult men and women, youth and children ≥6 years of
age who are seeking a PHCC for sore throat with sus-
pected tonsillitis and meeting the criteria in accordance
with current treatment recommendations for streptococ-
cal pharyngotonsillitis, i.e. 3–4 Centor criteria (fever ≥
38.5, tender lymph nodes, coatings of the tonsils and ab-
sence of cough) and a positive rapid antigen detection
test (RADT) for GAS will be included in the study [15].
Exclusion criteria
A patient is not eligible for inclusion if any of the follow-
ing criteria apply: 1) Signs of serious illness according to
pre-specified criteria, 2) hypersensitivity to penicillin, 3)
chronic illness that significantly impair the immune sys-
tem, 4) immunomodulating treatment, 5) treatment with
antibiotics for pharyngotonsillitis during the last month
(relapse), 6) any antibiotic treatment during the last 72 h
before inclusion, 7) difficulty swallowing tablets, 8) any
other cause which, according to the physician’s judg-
ment, makes it unsuitable for the patient to participate
in the study.
Intervention
Patients will be randomized to treatment with penicillin
V four times daily for 5 days or three times daily for
10 days. The dosages for different weight groups are pre-
sented in Table 1.
Randomization
Randomization within blocks for each PHCC separately
was performed by a statistician at The Public Health
Agency of Sweden. Sealed envelopes with unique num-
bers and allocated treatment were distributed to each of
the 17 participating PHCCs.
Context and procedure
Study procedures are presented in Table 2.
Visit one
Patients presenting with sore throat will be clinically exam-
ined by a physician. In case of suspected faryngotonsillitis
and 3–4 Centor criteria a RADT for GAS will be per-
formed. Patients with a positive RADT test for GAS who
meet all the inclusion criteria, and none of the exclusion
criteria, will be asked to participate in the trial. After signed
informed consent, by patient or guardian, the patient will
be asked about medical history, demographic data, previous
antibiotic exposure and concomitant drug treatment.
A throat swab for semi quantitative cultures of
streptococcus group A, C and G will be performed.
After randomization to intervention group 5 or 10 days
the physician prescribes penicillin V which the patient
will retrieve from the pharmacy. A patient diary is
handed out which the patient or guardian is asked to fill
in until the follow-up visit, five to seven days after treat-
ment discontinuation.
Demographic data and clinical data will be recorded in
a case report form (CRF) by study personnel. In
addition, data regarding intake of penicillin V doses and
Table 1 Penicillin V dosing schedule
Body weight Dosage 5 days treatment Dosage 10 days treatment
>40 kg 800 mg × 4 1000 mg × 3
20–40 kg 500 mg × 4 500 mg × 3
10–20 kg 250 mg × 4 250 mg × 3
Table 2 Study procedures for both intervention groups,
penicillin V given four times daily for 5 days or three times daily
for 10 days
















































aFollow-up of adverse events which were ongoing at previous contact
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analgesics, presence of sore throat and fever, adverse
events etc. is filled in daily by each patient or guardian
in the diary.
Test-of-cure visit
A test-of cure (TOC) visit will be performed at the
PHCC 5 to 7 days after completion of antibiotic treat-
ment. Clinical judgement of throat status, a new RADT
and culture, and recording of adverse events will be
performed.
Follow-up controls
Follow-up controls will be done by a telephone call 1
month (28–35 days) and 3 months after the last treat-
ment day. Throat symptoms, potential relapses and
complications will be monitored as well as adverse
events ongoing at previous visits.
Outcomes
Primary outcomes
The primary outcome is clinical cure 5–7 days after dis-
continuation of antibiotic treatment (TOC). The patients
will be asked about throat symptoms and a clinical
judgement will be performed by the investigator. Clinical
cure is defined as complete recovery without remaining/
residual symptoms or clinical findings of pharyngotonsil-
litis or symptomatic relapse at TOC [15].
Secondary outcomes
The secondary outcomes are bacteriological eradication
according to the culture taken at the TOC, time to relief
of symptoms according to the patient diary, frequency of
relapses one month after first diagnosis, frequency of
complications during the study period as well as pattern
of adverse events.
Definitions




The power calculation is based on the assumption of
90 % clinical recovery in the reference group and no dif-
ference between the two groups. The non-inferiority
limit is set to minus 10%, the confidence level (two-
sided) to 95 %, the power to 85 % and the distribution
between the groups to 1/1. Based on these presump-
tions, 324 evaluable patients (162 in each group) are
needed to be able to demonstrate non-inferiority be-
tween treatment groups. Presuming that 25 % of the in-
cluded patients will not be possible to evaluate 432
(324*(1/0.75)) patients are needed to be included.
All effect variables will be analyzed for per protocol
population (PP) as well as for the modified intention to
treat (MITT) population as sensitivity analysis.
Safety
Patterns of adverse events between the two treatment
groups will be evaluated and analysed descriptively. Ac-
tive surveillance of adverse events will be done by a
physician at TOC and by self-reporting by the patient/
guardian in the patient diary. At the follow-up controls
1 and 3 months after discontinuation of treatment, pa-
tients will be asked about adverse events that are still
ongoing at the previous visit.
Monitoring
Monitoring according to GCP/ICH will be performed by
trained personnel allocated by the sponsor, The Public
Health Agency of Sweden.
Table 3 Definitions of outcome measures
Term Definition
Clinical cure Clinical judgement by physician 5–7
days after discontinuation of
treatment. Patient completely
recovered with no remaining/residual
symptoms or clinical findings of
pharyngotonsillitis or symptomatic
relapse at TOC.
Therapeutic failure None or inadequate clinical effect
during treatment period.
Not evaluable for primary
outcome
Follow-up after discontinuation of
treatment is missing.
Relapse Symptomatic pharyngotonsillitis
within one month after first diagnosis,
according to clinical judgement by
physician 1) antibiotic treatment




and including the TOC visit, following
at least 1 day without symptoms after
initial treatment, will be judged as
early relapse.
Complication with suspected
relation to the primary infection
For example peritonsillitis, acute otitis
media or sinusitis during the study
period, i.e. until the last follow-up
visit.
Bacteriological cure Absence of GAS in culture. If culture
is missing, a negative RADT.
Asymptomatic carriage of GAS Presence of GAS in culture from
patient without throat symptoms. If
culture is missing, a positive RADT.
Symptomatic infection of GAS Presence of GAS in culture from
patient with throat symptoms. If
culture is missing, a positive RADT.
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Ethical issues
It is important to include children in clinical trials, espe-
cially since children often suffer from infections and
therefore are treated with antibiotics more often than
other age groups. The lower age limit 6 years was
chosen based on presumed ability to swallow tablets,
since exposure is easier to control with tablets than with
oral suspension.
We consider that there are no risks to participate in
the study, regardless of age. The sampling is simple and
follow the normal routines at the PHCCs. Both treat-
ment alternatives are expected to be effective against the
infection. A shorter treatment regimen could include
benefits in form of less adverse events and less distur-
bances in the human microbiota. In addition, patient ad-
herence to the treatment may improve with shorter
treatment duration.
Discussion
In the era of increasing antimicrobial resistance and the
shortage of new antimicrobial agents it is necessary to
revisit old antibiotics to ensure that they are used cor-
rectly and to their full potential. Important old drugs de-
serve to be rigorously tested according to today’s
standards and requirements for clinical studies. Old anti-
microbial drugs are often associated with inadequate
knowledge on PK/PD and lack of optimized dosing regi-
mens based on randomized controlled clinical trials.
Since old antibiotics are usually out of patent protec-
tion, financial incentives to perform the necessary stud-
ies are lacking. Thus, public funding is often the only
option available [16]. For the current study, funded by
the Swedish government, an initial systematic review to
identify knowledge gaps was performed, followed by a
structured prioritizing process by independent experts,
in order to select the most needed non-clinical and clin-
ical studies.
There is currently no substantial scientific evidence to
recommend less than 10 days treatment of penicillin V
against streptococcal pharyngotonsillitis. A shorter treat-
ment period though, with lower total antibiotic expos-
ure, is expected to reduce the risk of ecological
disturbance on the human microbiota [17] and possibly
improve patient adherence [13].
One possible disadvantage with a shorter treatment
duration could be an increased risk for relapses, since
the time with protection against a new infection is
shorter. Furthermore, it could be argued that the daily
dose for the 5-day treatment is slightly higher than the
recommended daily dose, which may increase the risk
for adverse events. However, there is extensive clinical
experience of even higher doses in treatment of other in-
fections like acute otitis media, sinusitis, and dental
infection, justifying the safety profile of penicillin V also
at high doses.
Overall we believe that this study, facilitated by public
funding, may contribute with important knowledge and
may have a substantial impact on public health. If a shorter
and more potent treatment regimen is shown to be equiva-
lent with the normal 10 day regimen this can imply great
advantages for both patients (resistance, adverse events,
adherence) and the community (resistance, drug costs).
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